KT-621 parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively WATERTOWN, Mass., (GLOBE NEWSWIRE) -- Kymera ...

The DWP has confirmed the full list of 24 skin conditions that could qualify for Personal Independence Payment (PIP), worth up to £114 a week ...

The DWP has confirmed the full list of 24 skin conditions that could make someone eligible for PIP weekly payments. Here are ...

TARRYTOWN, N.Y. and PARIS, March 24, 2026 (GLOBE NEWSWIRE)-- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan ...

SAN FRANCISCO -- Perioperative sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) achieved a "promising" clinical complete response rate, as well as bladder preservation, in nearly 40% of ...

Regeneron (REGN) closed slightly lower yesterday after reporting Q4 2025 results that were slightly better than the market consensus, and providing expense guidance for 2026. However, there were no ...

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and ...

DEAR DR. ROACH: I am a 73-year-old woman who is in otherwise good health, but I was diagnosed with bullous pemphigoid, a rare autoimmune disease, in January 2022. I have been treated by three ...

TUESDAY, June 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...